This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kocabas, N. A. Articles by Karakaya, A. E. Search for Related Content PubMed PubMed Citation Articles by Kocabas, N. A. Articles by Karakaya, A. E. Social Bookmarking                         What's this?

N-Acetyltransferase (NAT2) Polymorphism and Breast Cancer Susceptibility: A Lack of Association in a Case-Control Study of Turkish Population

Neslihan Aygün Kocaba¹
Semra arda¹
Suzanne Cholerton²
Ann K. Daly²
Ali Esat Karakaya¹

¹ Department of Toxicology, University of Gazi, Pharmacy Faculty, Ankara, Turkey
² Department of Pharmacological Sciences, University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, United Kingdom

Correspondence: Address correspondence to Dr. Neslihan Aygün Kocaba, Gazi University, Faculty of Pharmacy, Department of Toxicology, 06330 Hipodrom, Ankara, Turkey. E-mail:neslihan{at}gazi.edu.tr orneslihanak{at}hotmail.com

Increased exposure to environmental carcinogens, including several aromatic and heterocyclic amines (HAs), is suspected to be one factor contributing to incidence of breast cancer. The N-acetyltransferase 2 (NAT2) acetylation polymorphism have been associated with a number of drug-induced toxicities and cancer in various tissues, resulting from decreased capacity to activate/deactivate several aromatic amine, hydrazine drugs, as well as HA carcinogens. Ethnic differences exist in NAT2 genotype frequencies, which may be a factor in cancer incidence. Our present case-control study in Turkey was performed to explore the association between NAT2 genetic polymorphism and individual susceptibility to breast cancer. The NAT2 genotypes (*4, *12A, *5A, *5B, *5C, *6, *7) were determined using the polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) assay in 84 breast cancer patients and 103 healthy controls, and 50% and 56.3%, respectively, were found to be slow acetylator genotypes. There was no significant difference in risk for breast cancer development among patients with rapid and slow acetylators, with adjusted odds ratio 0.78 (95% confidence interval 0.44 to 1.38). Also, risk was not affected by different variables. To our knowledge, this is the first genetic study on the association of NAT2 genotypes with breast cancer in the Turkish population, and this finding showed that NAT2 polymorphism does not play an important role in breast cancer risk of Turkish women by altering the capacity in deactivation of environmental carcinogens, even though small sample size and wide confidence interval.

Key Words: Acetylation Polymorphism • Breast Cancer • Heterocyclic Amine • NAT2 Gene • Turkish Population

International Journal of Toxicology, Vol. 23, No. 1, 25-31 (2004)
DOI: 10.1080/10915810490275053


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?